logo-loader

Stirling Products agrees to sell controlling interest in TeleMedCare for A$3m

Published: 23:27 21 Jun 2011 EDT

no_picture_pai

Stirling Products (ASX: STI) has exchanged a conditional purchase offer term sheet with Grupo Neat of Spain for the sale of 80% of the TeleMedCare (TMC) system for A$3 million.

TMC provides the only viable multi-user vital signs monitoring service/device in the world and has attracted interest from a number of major corporations.

The term sheet is subject to due diligence and the agreement of the respective Boards to the transaction.

Under the agreement the company must ensure that the sale be clear of all encumbrances, and present a balance sheet free of debt, promissory notes  and other liabilities.

Pending completion of this transaction, Stirling Products will seek to achieve a TeleMedCare structural reorganisation and cause TeleMedCare Pty Ltd to cease trading, whilst its affairs are formally addressed pending the potential sale.

TeleMedCare Holdings Pty Ltd and its subsidiary, MedCare Pty Ltd, which controls the TeleMedCare Intellectual Property, will continue to trade.

The TMC system delivers sophisticated health management in multi-user clinical and community settings, as well as medications management systems in residential care facilities.

The company has recently been awarded of the internationally coveted dual ISO 13485:2003 and CMDCAS Certification for the design, development, manufacture, distribution and service provision of multi-parameter telehealth monitors.

The certification greatly increases the global regulatory acceptance of the company’s products and services and represents a significant milestone for Stirling Products.

In addition to this news, the company has just been advised that Health Care NZ has published results of a successful e-Health trial using TeleMedCare.

In the trial half the chronically ill parties used TeleMedCare for daily vital signs monitoring whilst the other half continued under traditional care.

Despite being only a 12 month trial, it was significant with 10% of the TeleMedCare daily monitored chronically ill group dying compared to 40% in the control group.

Australian Strategic Materials signs US$600 million LoI

Rowena Smith, CEO and managing director of Australian Strategic Materials Ltd (ASX:ASM, OTC:ASMMF), joins Jonathan Jackson in the Proactive studio to discuss the company’ s Dubbo Project, in Central West New South Wales. This project aims to extract and process critical minerals and rare earth...

4 hours, 44 minutes ago